New hope for Tough-to-Treat lung cancer: experimental drug challenges standard chemo
NCT ID NCT06927986
Summary
This study is testing if a new drug called SYS6010 works better and is safer than standard platinum-based chemotherapy for people with advanced non-small cell lung cancer. It is for patients whose cancer has a specific genetic change (EGFR mutation) and has continued to grow despite previous targeted therapy. The trial will involve about 380 participants and directly compares the two treatment approaches.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.